Patients with inflammatory bowel diseases (IBDs) suffer from higher mortality rates and are at an increased risk of cancer when they develop new-onset primary sclerosing cholangitis, a recent study has found.
The associations of anxiety, depression, and chronic inflammation with aortic pulse wave velocity (aPWV) and systolic blood pressure (SBP) indicate the first evidence of a brain–gut–vascular axis and new potential targets for treatment in patients with Crohn’s disease (CD), reveals a study.
Use of nonvitamin K antagonist oral anticoagulants (NOACs), particularly dabigatran, is associated with a significantly reduced risk of laboratory-based liver injury among patients with atrial fibrillation (AF) when compared with warfarin, results of a recent study have shown.
A multimodal intervention using nonopioid analgesics results in reduced intravenous opioid (IVOPI) exposure, length of stay (LOS), and 30-day readmission rates for hospitalized patients with inflammatory bowel disease (IBD), a study has shown.
Infection with Helicobacter pylori is associated with a higher risk of developing advanced colorectal neoplasia (AN), reports a study. Such correlation is consistent in both serological and histologic assessments of H. pylori infection.
Two doses of the novel potassium‐competitive acid blocker tegoprazan show comparable healing effects on gastric ulcers as lansoprazole, while having a favourable safety profile, according to the results of a phase III trial.
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.